Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
9 studies found for:    CRISPR
Show Display Options
Rank Status Study
1 Not yet recruiting A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ
Condition: Human Papillomavirus-Related Malignant Neoplasm
Interventions: Biological: TALEN;   Biological: CRISPR/Cas9
2 Recruiting Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances
Condition: HIV-1-infection
Intervention: Genetic: CCR5 gene modification
3 Not yet recruiting A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Conditions: B Cell Leukemia;   B Cell Lymphoma
Intervention: Biological: UCART019
4 Recruiting PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Interleukin-2;   Other: PD-1 Knockout T Cells
5 Not yet recruiting PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
Condition: Invasive Bladder Cancer Stage IV
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
6 Not yet recruiting PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
7 Not yet recruiting PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
8 Recruiting PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: Cyclophosphamide;   Other: PD-1 Knockout T Cells;   Drug: Interleukin-2
9 Recruiting PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
Conditions: Stage IV Gastric Carcinoma;   Stage IV Nasopharyngeal Carcinoma;   T-Cell Lymphoma Stage IV;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Interleukin-2

Study has passed its completion date and status has not been verified in more than two years.